Brookline Capital Markets Thinks NLS Pharmaceutics’ Stock is Going to Recover

Brookline Capital Markets analyst Kumaraguru Raja initiated coverage with a Buy rating on NLS Pharmaceutics (NLSPResearch Report) today and set a price target of $12.00. The company’s shares closed last Tuesday at $2.66, close to its 52-week low of $2.06.

According to, Raja is a 4-star analyst with an average return of 15.6% and a 41.9% success rate. Raja covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals, Arcturus Therapeutics, and Outlook Therapeutics.

NLS Pharmaceutics has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.35 and a one-year low of $2.06. Currently, NLS Pharmaceutics has an average volume of 492.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. The company focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company’s tangible assets are held in the United States.